Don’t miss out - Get your tickets early!

Join this FREE, 75-minute online webinar to gain access to insights and learn about ground breaking treatments to chronic mental health conditions.

Join this FREE WEBINAR presented by Dr Bessel Van der Kolk (USA)

Topic: Understanding and healing trauma through psychedelic-assisted therapy

MDMA-assisted therapy is going mainstream: Bessel van der Kolk is one of the world’s leading trauma researchers, and author of the seminal book on trauma ‘The body keeps the score’. He is also involved in two large multi centre phase-3 studies on MDMA-assisted therapy for post-traumatic stress disorder (PTSD). This makes his perspectives on this new treatment extremely intriguing.

In this webinar, Bessel van der Kolk will share his experiences as the principal investigator at the Boston site. He will also share his deeply personal experiences from his own training where he received MDMA-assisted therapy himself.
First and foremost you will learn a lot about both published and unpublished data from the MDMA-assisted therapy for PTSD trials.
And we will touch on both possibilities and pitfalls with MDMA-assisted psychotherapy both on an individual and societal level.

“For me, it was a transformative experience where I got much more respect for what it’s like to actually carry all this pain that people dump on you. You get these transformations that I have not seen with any other treatment modality.” Bessel van der Kolk

Date: Wednesday 12 October 2022

Time: 9:55am for 10:00am start – 11:15am (incl Q&A) (AEDT)

The presentation WILL BEGIN AT 10:00am.

Location: Online. A link will be emailed to you with the viewing details

Don’t miss out - Get your tickets early!

More about medicinal psychedelic treatments:

Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.

The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.

More about the presenters

Dr Bessel Van der Kolk (USA)

Psychiatrist, Author, and Researcher

Bessel van der Kolk MD spends his career studying how children and adults adapt to traumatic experiences, and has translated emerging findings from neuroscience and attachment research to develop and study a range of treatments for traumatic stress in children and adults.

In 1984, he set up one of the first clinical/research centers in the US dedicated to study and treatment of traumatic stress in civilian populations, which has trained numerous researchers and clinicians specializing in the study and treatment of traumatic stress, and which has been continually funded to research the impact of traumatic stress and effective treatment interventions. He did the first studies on the effects of SSRIs on PTSD; was a member of the first neuroimaging team to investigate how trauma changes brain processes, and did the first research linking BPD and deliberate self-injury to trauma and neglect in early childhood.

Much of his research has focused on how trauma has a different impact at different stages of development, and that disruptions in care-giving systems have additional deleterious effects that need to be addressed for effective intervention. In order to promote a deeper understanding of the impact of childhood trauma and to foster the development and execution of effective treatment interventions, he initiated the process that led to the establishment of the National Child Traumatic Stress Network (NCTSN), a Congressionally mandated initiative that now funds approximately 150 centers specializing in developing effective treatment interventions, and implementing them in a wide array of settings, from juvenile detention centers to tribal agencies, nationwide.

Support psychedelic research and therapy development

By donating to Mind Medicine Australia, you will be helping us to accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support.

Please click here to make a tax-deductible donation.

Disclaimer

Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example facebook, instagram and zoom private and public chat forms during the webinar). Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters.

Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses.